Travere Therapeutics (TVTX) Depreciation & Amortization (IS) (2013)
Travere Therapeutics posted quarterly Depreciation & Amortization (IS) of $56865.0 for Q4 2013, up 5.66% on a QoQ basis from $53821.0 in Q3 2013.
Travere Therapeutics (TVTX) has 1 years of Depreciation & Amortization (IS) data on file, last reported at $56865.0 in Q4 2013.
- For the quarter ending Q4 2013, Depreciation & Amortization (IS) changed N/A year-over-year to $56865.0; the trailing twelve-month figure through Dec 2013 stood at $215993.0 (changed N/A YoY), and the FY2013 full-year result was $215993.0, up 72.95% from the prior year.
- Depreciation & Amortization (IS) for Q4 2013 stood at $56865.0, up from $53821.0 in the prior quarter.
- Across five years, Depreciation & Amortization (IS) topped out at $56865.0 in Q4 2013 and bottomed at $52168.0 in Q1 2013.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dep. & Amort. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 127,436.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 12.00 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Travere Therapeutics | 4.34 Bn | 4.26 Bn | 102.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2013 | 56,865.00 |
| Sep 30, 2013 | 53,821.00 |
| Jun 30, 2013 | 53,139.00 |
| Mar 31, 2013 | 52,168.00 |